Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMNN
stocks logo

IMNN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-2.025
-37.89%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for Imunon, Inc. (IMNN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -30.50%.
EPS Estimates for FY2025
Revise Downward
down Image
-54.48%
In Past 3 Month
Stock Price
Go Down
down Image
-30.50%
In Past 3 Month
Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.000
sliders
Low
12.00
Averages
12.00
High
12.00
Current: 4.000
sliders
Low
12.00
Averages
12.00
High
12.00
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
2025-05-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
2025-05-19
downgrade
Buy
to
Hold
Reason
Boral Capital
D. Boral
Buy
downgrade
$29 -> $17
2025-05-13
Reason
Boral Capital
D. Boral
Price Target
$29 -> $17
2025-05-13
downgrade
Buy
Reason
HC Wainwright & Co.
Emily Bodnar
Strong Buy
Reiterates
$14
2025-03-26
Reason
HC Wainwright & Co.
Emily Bodnar
Price Target
$14
2025-03-26
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$29
2025-03-24
Reason
D. Boral Capital
Jason Kolbert
Price Target
$29
2025-03-24
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$29
2025-02-27
Reason
D. Boral Capital
Jason Kolbert
Price Target
$29
2025-02-27
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$29
2025-02-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
$29
2025-02-19
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Imunon Inc (IMNN.O) is -0.78, compared to its 5-year average forward P/E of -1.44. For a more detailed relative valuation and DCF analysis to assess Imunon Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.44
Current PE
-0.78
Overvalued PE
0.20
Undervalued PE
-3.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
40.73
Current PS
0.00
Overvalued PS
110.83
Undervalued PS
-29.37
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IMNN News & Events

Events Timeline

(ET)
2025-11-13
07:46:23
Imunon Anticipates Sufficient Funds to Support Operations Through Q1 2026
select
2025-11-13
07:46:08
Imunon Announces Q3 Earnings Per Share of $1.16 Compared to $3.76 from the Previous Year
select
2025-11-10 (ET)
2025-11-10
07:59:42
Imunon Highlights Advancements on IMNN-001 During R&D Day
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-14NASDAQ.COM
Imunon (IMNN) Q3 2025 Earnings Conference Call Transcript
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
9.5
11-13Newsfilter
IMUNON Releases Financial Results for Q3 2025 and Offers Business Update

  • R&D Day Highlights: IMUNON showcased significant progress in its Phase 3 OVATION 3 Study for IMNN-001, a potential frontline immunotherapy for advanced ovarian cancer, emphasizing strong survival data and a favorable safety profile.

  • Financial Performance: The company reported a net loss of $3.4 million for Q3 2025, a decrease from the previous year, with operating expenses also down by 30%, indicating improved financial management.

  • Clinical Advancements: IMNN-001 demonstrated the ability to create a "hot" tumor microenvironment, enhancing immune responses and showing promising results in ongoing clinical trials, including a notable median overall survival benefit.

  • PlaCCine Technology Development: IMUNON is advancing its PlaCCine DNA vaccine technology, presenting positive proof-of-concept data at various conferences, and is seeking partnerships to enhance its vaccine development efforts.

[object Object]
Preview
1.0
11-11Newsfilter
IMUNON's Public Webcast Showcases Resilience and Innovation in the Quest for the First Approved Ovarian Cancer Immunotherapy

  • Webcast Event: IMUNON, Inc. hosted a public webcast featuring cancer experts discussing the potential of their DNA-mediated immunotherapy, IMNN-001, for treating advanced ovarian cancer, with recordings and slides available on their website.

  • Company Overview: IMUNON is a clinical-stage biotechnology company focused on innovative treatments using non-viral DNA technology, including their lead program IMNN-001 and a COVID-19 booster vaccine (IMNN-101).

  • Clinical Trials: IMNN-001 has completed a Phase 2 trial and is currently in Phase 3 trials, demonstrating the company's commitment to advancing therapies for difficult-to-treat conditions.

  • Forward-Looking Statements: The company issued a caution regarding forward-looking statements, highlighting the risks and uncertainties associated with clinical trials and the development of their therapies.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Imunon Inc (IMNN) stock price today?

The current price of IMNN is 4 USD — it has increased 1.14 % in the last trading day.

arrow icon

What is Imunon Inc (IMNN)'s business?

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

arrow icon

What is the price predicton of IMNN Stock?

Wall Street analysts forecast IMNN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Imunon Inc (IMNN)'s revenue for the last quarter?

Imunon Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Imunon Inc (IMNN)'s earnings per share (EPS) for the last quarter?

Imunon Inc. EPS for the last quarter amounts to -1.01 USD, decreased -76.94 % YoY.

arrow icon

What changes have occurred in the market's expectations for Imunon Inc (IMNN)'s fundamentals?

The market is revising No Change the revenue expectations for Imunon, Inc. (IMNN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -30.50%.
arrow icon

How many employees does Imunon Inc (IMNN). have?

Imunon Inc (IMNN) has 25 emplpoyees as of December 05 2025.

arrow icon

What is Imunon Inc (IMNN) market cap?

Today IMNN has the market capitalization of 12.28M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free